Please ensure Javascript is enabled for purposes of website accessibility
REVIEW PAPER
A new approach to endometrial cancer subtyping – a hope for a milestone in correct patient triaging
 
More details
Hide details
1
Department of Gynaecology and Obstetrics, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
 
2
Department of Gynaecology and Obstetrics, Provincial Integrated Hospital, Kielce, Poland
 
 
Submission date: 2023-03-29
 
 
Final revision date: 2023-08-16
 
 
Acceptance date: 2023-08-17
 
 
Publication date: 2023-09-30
 
 
Medical Studies 2023;39(3):267-271
 
KEYWORDS
TOPICS
ABSTRACT
Endometrial cancer is the most common cancer of the female genital organs. For many years the prognosis was based on histopathological grade and type. The pathological identification of endometrial carcinomas included two types. Type I – endometrioid (EEC), similar to the endometrium – was characterized by genetic predisposition, obesity, polycystic ovary syndrome, anovulatory cycles, and irregular menstruation resulting from hyperestrogenism, which is the main predisposing factor for the development of type I EC. Type II included serous, clear cell, and undifferentiated carcinomas. Here were observed older patient’s age, higher clinical stage to compare with non-endometrioid histology, and finally poorer prognosis. The Cancer Genome Atlas (TCGA) study found mutations in several endometrioid and serous cancer genes. The TCGA has identified four molecular subclasses based on somatic mutation burden and copy number variations. Recent data show the prognostic value of TCGA subclasses because they correlate with patient survival.
REFERENCES (28)
1.
Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA. Evolving roles of histologic evaluation and molecular/genomic profiling in the management of endometrial cancer. J Natl Compr Canc Netw 2018; 16: 201-209.
 
2.
van den Heerik AS, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer 2021; 31: 594-604.
 
3.
Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynecol Amp Obstet 2008; 101: 205-210.
 
4.
Mitric C, Bernardini MQ. Endometrial cancer: transitioning from histology to genomics. Curr Oncol 2022; 29: 741-757.
 
5.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol 2021; 160: 817-826.
 
6.
Levine D, Mardis E, Network TC. Late-Breaking Abstract 4: The Cancer Genome Atlas (TCGA) project on endometrial carcinoma: initial data and preliminary genomic analysis. Gynecol Oncol 2012; 125: 772.
 
7.
Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, Zullo F. TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol 2019; 155: 374-383.
 
8.
Adamczyk-Gruszka O, Horecka-Lewitowicz A, Strzele- cka A, Wawszczak-Kasza M, Gruszka J, Lewitowicz P. The roles of TP53 and FGFR2 in progress made treating endometrial cancer. Diagnostics 2022; 12: 1737.
 
9.
Rosa RC, Yurchenko AA, Chahud F, Ribeiro-Silva A, Brunaldi MO, Silva Jr WA, Kannouche PL, Nikolaev S, Fer- raz VE. First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene. Genet Mol Biol 2020; 43: e20200100.
 
10.
León-Castillo A, Britton H, McConechy MK, McAlpi- ne JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 2020; 250: 323-335.
 
11.
Suerink M, Kilinç G, Terlouw D, Hristova H, Sensuk L, van Egmond D, Farina Sarasqueta A, Langers AM, van Wezel T, Morreau H, Nielsen M. Prevalence of mismatch repair deficiency and Lynch syndrome in a cohort of unselected small bowel adenocarcinomas. J Clin Pathol 2020; 74: 724-729.
 
12.
Reske JJ, Wilson MR, Holladay J, Siwicki RA, Skalski H, Harkins S, Adams M, Risinger JI, Hostetter G, Lin K, Chandler RL. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis. PLOS Genet 2021; 17: e1009986.
 
13.
Yasin HK, Taylor AH, Ayakannu T. A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer. Cancers 2021; 13: 2149.
 
14.
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1 -mutated endometrial cancer. Mol Carcinog 2021; 60: 511-523.
 
15.
Ledinek Ž, Sobočan M, Knez J. The role of CTNNB1 in endometrial cancer. Dis Markers 2022; 1442441. https://doi.org/10.1155/2022/1....
 
16.
Wortman BG, Bosse T, Nout RA, Lutgens LC, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KA, Verhoeven-Adema KW, Smit VT, Creutzberg CL. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol 2018; 151: 69-75.
 
17.
Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
 
18.
Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2014; 107: 402.
 
19.
Adamczyk-Gruszka O, Horecka-Lewitowicz A, Gruszka J, Wawszczak-Kasza M, Strzelecka A, Lewitowicz P. Endometrial cancer in aspect of forkhead box protein contribution. Int J Environ Res Public Health 2022; 19: 10403.
 
20.
Adamczyk-Gruszka O, Horecka-Lewitowicz A, Gruszka J, Wawszczak-Kasza M, Strzelecka A, Lewitowicz P. FGFR-2 and epithelial–mesenchymal transition in endometrial cancer. J Clin Med 2022; 11: 5416.
 
21.
Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
 
22.
Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol 2017; 30: 1032-1041.
 
23.
de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven- Adema KW, Putter H, Creutzberg CL, Smit VT. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol 2018; 29: 424-430.
 
24.
RAINBO Research Consortium. Int J Gynecol Cancer 2023; 33: 109-117.
 
25.
Samstein RM, Riaz N. The DNA damage response in immunotherapy and radiation. Adv Radiat Oncol 2018; 3: 527-533.
 
26.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017; 23: 3711-3720.
 
27.
Daniilidis A, Margioula-Siarkou C, Margioula-Siarkou G, Papandreou P, Papanikolaou A, Dinas K, Petousis S. Sentinel lymph node mapping in endometrial cancer to reduce surgical morbidity: always, sometimes, or never. Menopause Rev 2022; 21: 207-213.
 
28.
Bulsa M, Jankowska-Szabłowska S, Urasińska E. Immunohistochemical expression of PARP-1 in triple-negative endometrial cancer – a comparison of different score systems. Pol J Pathol 2022; 73: 330-337.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top